Yes. I could just say, generally speaking, that if you look at the portfolio of international vaccine candidates that the government has purchased, there has been an effort to make sure there are a number of each of the main different types of vaccines. The ones that have been approved are using messenger RNA, but there are other vaccines that are protein-based. There are viral vector-based vaccines. There are different major platforms for vaccine production.
In the same fashion, when it comes to the efforts to boost Canada's biomanufacturing capacity, there has been a deliberate effort to make sure there are investments going to different kinds of platforms. For example, Minister Champagne mentioned the investment in Medicago. Medicago is a plant-based, virus-like particle vaccine. He mentioned the investment in VIDO-InterVac. That's a protein subunit vaccine. If I look at the investment in Provenance therapeutics, I see that's a messenger RNA vaccine.
The efforts on biomanufacturing and the support the government has given to the various Canadian vaccine candidates to advance their clinical trial work have been across these various kinds of technologies. The idea is not to put all of our eggs in one basket. It's to have multiple eggs and multiple baskets.